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ABSTRACT
Urinary tract infections (UTI) are the most common serious bacterial infections in young children. 
These UTIs have a high association with vesicoureteric reflux (VUR). The pathophysiology of 
VUR’s renal sequelae, its investigation and management is presently undergoing a reassessment. 
This review documents these changes focusing on compelling new data. With regard to the 
need for and benefit of imaging procedures in children with UTIs we present an algorithm for 
investigation that is tailored to the African context. The value of continuous antibiotic prophylaxis 
is questioned and the role of injectable ureteric bulking is discussed with reference to the Swedish 
Reflux Trial. 
Key Words: Vesicoureteric reflux, children, etiology, pathophysiology, investigation, 
managment 
Corresponding Author: Dr. John Lazarus, Paediatric Urology, Red Cross Children’s Hospital, 
University of Cape Town, South Africa, Email: may1968@geocities.com       
Article Info : Date received: 4/7/2010                           Date accepted (after revision): 24/8/2010 
INTRODUCTION                                                    
The traditional modes of investigation and 
management of primary vesicoureteric reflux 
(VUR) in children is undergoing a dramatic 
revision. VUR has been called the “prostate 
cancer” of Paediatric Urology, recognition 
that VUR has been over investigated and 
perhaps in many cases over treated.
This paper aims to define contemporary 
best practice for children with VUR based 
on the emerging available evidence. VUR’s 
etiology, pathophysiology, presentation, 
investigation and management will be 
discussed.
Paquin (1959) first proposed that a short 
intramural ureteric tunnel accounted for 
“lateral ectopia” and this is what we define as 
primary VUR.26 It is estimated that as many 
as 8% of girls and 2% of boys will have a 
urinary tract infection (UTI) by the age 
of 7 years19. A third of these UTIs are 
associated with VUR17. In our African 
context the incidence of VUR is suspected to 
be lower than this, as American data suggests 
that black children have a 10-fold lower VUR 
incidence than white children27.
Traditional clinical approach: Two 
milestones have guided the traditional clinical 
approach to VUR. The first was a landmark 
study of VUR in a pig model by Phillip 
Ransley of Great Ormond Street Children’s 
Hospital, London24. He demonstrated a 
simple equation that has stood the test of time. 
VUR when associated a UTI leads to chronic 
pyelonephritis with resultant renal scarring, 
hypertension and eventually end stage renal 
disease. This work provided the rationale 
for antibiotic prophylaxis since VUR in the 
absence of infection is a benign entity.
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history of VUR and the publication of 4 well 
designed clinical studies.
Ransley’s work had provided compelling 
proof of the dangers of VUR, yet newer work 
has cast doubt on the extent of the association 
of VUR, UTIs and renal damage. It has been 
shown that “dilating” VUR (i.e. Grades III-V) 
have a six fold greater chance of producing 
renal scarring than Grades I-II3. Yet this 
seemingly obvious linear association is not 
always borne out. Renal scarring occurs in 
some children in the absence of VUR and 
yet does not occur in many cases of severe 
VUR4. Other factors must thus be at play 
since longitudinal studies suggest that renal 
damage exists even before the 1st UTI and 
that in fact few new abnormalities arise after a 
UTI17. This suggests that the pathophysiology 
of the renal parenchymal anomaly associated 
with VUR may in fact exist antenatally – the 
so-called reflux-congenital renal hypoplasia/
dysplasia syndrome18. Williams et al have 
postulated that rather than UTI or VUR, it is 
this parenchymal anomaly that is the key to 
the pathophysiology17.
The International Reflux Study (IRS) 
represents the second milestone in our 
traditional understanding of VUR1, 2 The 
IRS randomised children to either surgical 
reimplantation combined with antibiotic 
prophylaxis versus prophylaxis alone. The 
study showed no difference in the rate of 
recurrent UTI’s or renal scarring, therefore 
adopting a policy of prophylaxis as first-line 
therapy for VUR. However, febrile UTI’s (i.e. 
pyelonephritis) were lower in the surgery arm. 
This finding guided the practice that children 
who failed conservative treatment underwent 
surgery. The IRS thus represented a powerful 
stimulus to guide treatment of VUR and 
crucially provided a motivation for surgical 
intervention. Essentially, all children with 
VUR were placed on prophylactic antibiotics, 
and if this failed surgical correction was 
recommended.
The IRS’s impact on clinical practice 
can be seen from our own unpublished data 
over a 15 year period (1992 – 2007). During 
this period 190 children were treated for 
VUR. Of these the majority had Grades I – 
III VUR. Roughly, 50% of the total cohort 
either underwent immediate surgery or initial 
conservative treatment followed by surgery. 
This represents a high number of children 
undergoing surgery for VUR, an approach 
that has been questioned in recent literature.
A major limitation of the IRS was that it 
never included a placebo or observational 
arm21. Thus the superiority of prophylaxis or 
surgery over surveillance was never actually 
established. Furthermore, the data from the 
IRS and similar studies have undergone meta-
analysis and it is estimated that 15 children on 
prophylaxis need to be reimplanted to prevent 
1 febrile UTI at 5 years follow-up17.
To summarise, as Paediatric Urologists 
we have been basing many decades of VUR 
management on poorly controlled data, 
which had at best shown a marginal benefit 
for surgery.
Problems with the traditional management 
of VUR: Doubts regarding the traditional 
care of children with VUR began to surface 
with greater understanding about the natural 
Fig. 1: Natural history of VUR, from a population of 1,000,000 
children (assuming a prevalence of VUR of 3%)5.
105
HAVE WE OVERTREATED CHILDREN WITH VUR?
Regarding the natural history of VUR, it 
is recognized that most cases spontaneously 
resolve by the age of 2 years. As is shown in 
Fig. 1, an assumed  VUR prevalence of 3%, 
would yield an incidence of 30 000 children 
in a cohort of 1 million. Yet only 5 out of 
those million children would be expected to 
progress to end stage renal disease (ESRD)5. 
Malone has estimated that to prevent one case 
of ESRD, $5 million dollars will be s3pent to 
investigate otherwise healthy children6. 
To summarise, longitudinal VUR studies 
have cast doubt on the conventionally 
understood pathophysiology of VUR and 
hence the benefits of treatment. They point 
to VUR’s natural history in that most cases 
resolve, 30% will have recurrent UTI, but 
few develop major renal sequelae17.
Additional evidence of over treatment 
comes from four recent trials looking at 
the effect of antibiotic prophylaxis on UTI 
prevention. All studies surprisingly showed 
no reduction in UTIs with prophylaxis7-10 
These studies thus question the established 
first line role of antibiotic prophylaxis in the 
management of VUR.
This growing skepticism culminated in a 
Cochrane Collaboration review which made 
the startling conclusion that: “it is uncertain 
whether the treatment of children with VUR 
confers clinically important benefit11.
Revised guidelines for VUR investigation: 
If the evidence to treat VUR is inadequate, 
we should ask if the link between VUR, UTIs 
and renal scarring is significant enough to 
warrant detection. The answer to this vexing 
question must lie in less invasive and more 
selective investigation protocols.
The United Kingdom’s National Institute 
for Clinical Excellence (NICE) produced 
dramatically revised VUR guidelines in 
2007. These make reference to the fact that 
Fig. 2: Red Cross Children’s Hospital UTI investigation protocol. The need to confirm a UTI prior to investigation is emphasised, a renal 
sonar in all patients, but reservation of further imaging for those with abnormal sonar or recurrent UTI16.
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investigation of VUR in children is invasive, 
costly and often produces information of little 
clinical significance12.
Standard VUR investigation protocols 
have for decades required an MCUG 
in addition to ultrasound. Despite its 
invasiveness, the MCUG remains the second 
commonest investigation requested by 
Paediatric Urologists. In one study, girls who 
have undergone ureteric reimplant for VUR 
recalled the MCUG more than the surgery14. 
Additionally, concerns exist about the 
cancer risk associated with X-ray exposure. 
An MCUG has an estimated cancer risk in 
children of 1:250015. The deleterious effects 
of ionising radiation are well known. In 
children, especially, the goal is to use a dose 
that is “as low as reasonably achievable” (the 
ALARA principle)13.
These traditional approaches to 
investigation place emphasis on the MCUG 
in what has been termed the “bottom up 
approach”. Evidence has accumulated which 
supports rather a “top down approach”. 
Here renal status via nuclear imaging 
is prioritised.
The Red  Cross Children’s Hospital in 
Cape Town, South Africa has recently adopted 
a new protocol (Fig. 2). The protocol’s aims 
were two-fold. Firstly, it recognises evidence 
based changes in our understanding of VUR’s 
significance. Secondly, we wished to produce 
a protocol appropriate to a developing-world 
medical environment.
The 2007 NICE guidelines for the 
investigation of UTIs have caused great 
controversy in the UK with its dramatic 
reduction in imaging requirements. NICE’s 
protocol is more radical than the Red Cross 
Children’s Hospital’s guidelines in reducing 
imaging. With NICE guidelines patients over 
six months would not automatically get an 
ultrasound. 
Malone et al sought to test the new NICE 
protocol with traditional practice. They 
found that 83% of renal sonars required by 
traditional protocols would be classified by 
the new NICE guidelines as inappropriate. 
“Anomalies” were detected in only 2.6%, 
but these were typically of little clinical 
significance6. These data serve to support 
the claim of over investigation by traditional 
protocols.
VUR management revised: Traditionally, 
VUR management required long-term 
antibiotic prophylaxis with open ureteric 
reimplantation reserved for failures of 
conservative treatment. This has undoubtedly 
resulted in over treatment of some children. 
This raises the critical question of how can 
we select the few children in whom VUR 
is significant so as to avoid over treating 
the majority?
Previously, mention was made of trials 
that called into question the value of antibiotic 
prophylaxis. A recent well conducted 
Australian study, the PRIVENT trial, supports 
an ongoing  role for  prophylaxis (Fig. 3). Craig 
el al,19 randomized 600 children following 
their 1st UTI to either placebo or antibiotic 
prophylaxis. Their mean age was 14 months, 
64% were girls and 42% had proven VUR. 
They demonstrated a statistically significant 
6% reduction in the risk of febrile UTIs 
that was more pronounced at higher grades 
of VUR (Fig. 3). They thus concluded that 
prophylaxis is modestly effective.
The RIVUR study (Randomized 
Intervention for children with Vesico Ureteral 
Reflux) is a new well designed study that is 
presently recruiting. It aims to evaluate the 
effectiveness of prophylaxis in children with 
VUR after a 1st UTI21.
A third important and recently published 
VUR trial is the Swedish Reflux Study20. 
They randomised 600 patients, 66% of 
whom were girls who had proven dilating 
(Grade III-V) VUR to prophylaxis, 
surveillance alone or a STING (endoscopic 
ureteric bulking) procedure. Resolution 
of VUR at 2 years was 40%, 48% and 
71%, respectively (P=0.0002). and UTIs 
recurred in 19%, 57% (p=0.0002) and 
23%, respectively. The authors concluded 
that STING or prophylaxis is better than 
surveillance. Both febrile UTIs and renal scars 
were more common in the surveillance arm, 
particularly in girls.
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The Swedish study is important, because 
unlike previous studies that have compared 
antibiotics with surgery, it concludes that 
there is a favourable role for the STING 
procedure. Endoscopic treatment has good 
long-term results in preventing febrile UTIs. 
Stenberg et al followed STING patients for 
7-12 years after treatment and found a UTI 
incidence of only 3.4%28.
Finally, our ability to define those children 
at risk of scarring remains crude. VUR is a he-
ritable disease. In future, markers of genetic 
susceptibility to UTI in those with VUR will 
doubtless play a role. Unfortunately, while 
much is already known, definite markers for 
clinical use do not yet exist17.
CONCLUSION                                                        
We conclude that revised investigation 
protocols such as the one employed at 
Red Cross Children’s Hospital needs to be 
popularised, particularly the suggestion that 
MCUG is inappropriate after an initial febrile 
UTI.
Antibiotic prophylaxis provides marginal 
benefit for most children, particularly those 
with low grade VUR. It seems that, as the 
Swedish Reflux Study has shown; endoscopic 
treatment is a good choice to prevent UTIs 
and resultant scarring. Enthusiasm for 
STING in the developing world needs to be 
tempered by its cost. Hence there remains an 
ongoing role for open surgical reimplantation, 
particularly in Africa.                         
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Editorial Comment
While this manuscript does not provide new information, it is a very good review of current information for 
the management of vesicoureteral reflux (VUR) and how one can apply it to a specific population of patients 
with its own urinary tract infection and VUR characteristics.
We commend Dr. Lazarus for this concise summary of some of the contemporary issues surrounding the 
diagnosis and treatment of vesicoureteral reflux (VUR).  Clearly, VUR is fraught with overdiagnosis and 
overtreatment.  The classic, bottom-up approach may result in many negative, and unnecessary, VCUGs 
(and even ultrasounds as noted in the article).  In an effort to minimize this, the top-down approach has 
been developed and has gained popularity.  Further, there are conflicting reports on the utility of antibiotic 
prophylaxis as mentioned in the article.  A recent commentary by Peters perhaps best summarizes the 
philosophical issue with our diagnosis and management of VUR—that this is not a homogenous disease upon 
a homogenous population (1). 
Many patients with higher grades of VUR and urinary tract infections (UTI) will escape without renal scarring 
and many patients with lower grades of VUR may fare much worse.  In other words, VUR has different risk 
of renal injury for different patients, irrespective of the grade.  However, at this point, we cannot accurately 
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identify which patients will be significantly affected by VUR.  It is logical that we have elected, as a society, 
to offer overdiagnosis and treatment as this is seen as less egregious than underdiagnosis and treatment. 
Ultimately, our current tools are not sensitive or specific enough to neither prevent unnecessary tests and 
treatments nor predict the risk of reflux nephropathy.  Certainly, this is a function of the population for which 
these tools are used.  As noted in the article, Africans have a lower prevalence of VUR.  Hence, tools used 
in the US or Europe may result in a lower positive predictive value in Africa (and result in even higher rates 
of overdiagnosis and treatment).  Perhaps pre-testing identification of risk factors, such as dysfunctional 
voiding, C-reactive protein levels during a UTI, newer imaging techniques, and other advances may increase 
the sensitivity or further alter newer diagnostic algorithms and decrease the overdiagnosis and overtreatment 
of this disease.  However, this must be tailored to the population, and more specifically, the patient being 
evaluated.
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